Hemispherx Biopharma has executed an amended and restated agreement with Impatients, a Netherlands-based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.

myTomorrows, as Hemispherx’ exclusive service provider in Europe and Turkey, will perform EAP activities in Europe and Turkey to include the supply of rintatolimod for the treatment of Chronic Fatigue Syndrome (CFS) to patients with an unmet medical need.

The original agreement was executed on August 3, 2015, and then terminated by Hemispherx Biopharma on April 20, 2016, allowing both parties to renegotiate and rectify certain aspects of the original agreement.

Thomas K. Equels, CEO of Hemispherx said, “I am very enthusiastic about the possibilities moving forward with myTomorrows now that we have resolved all outstanding issues and have come to an agreement that is potentially mutually profitable for both companies.”

Rintatolimod is a member of a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.

myTomorrows provides services to patients and physicians in need of drugs in development and diagnostic tests. Through its Internet-based platform, myTomorrows provides uniform public information about early access programs, clinical trials and diagnostic tests to enhance data-driven decision-making and enable rational pharmacotherapy. myTomorrows also facilitates requests for diagnostic tests and drugs in development

Hemispherx Biopharma is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders.